College of Pharmaceutical Sciences, Southwest University, Chongqing, 400715, PR China.
College of Pharmaceutical Sciences, Southwest University, Chongqing, 400715, PR China.
J Ethnopharmacol. 2021 Jan 10;264:113377. doi: 10.1016/j.jep.2020.113377. Epub 2020 Sep 10.
Xianglian Pill (XLP), a traditional Chinese pharmaceutical preparation for the treatment of gastrointestinal disease, possessing anti-inflammatory, anti-microbial and analgesic activities, may represent a promising candidate for the treatment of antibiotic-associated diarrhea (AAD).
This study aimed to unravel the underlying mechanism of XLP on the amelioration of AAD.
AAD was induced by intragastric administration of a mixture of cefuroxime and levofoxacin (300 mg/kg. bw + 200 mg/kg. bw) for five consecutive days. Then AAD mice were treated with XLP at the dose of 500, 1000 and 2000 mg/kg. bw, respectively for 5 days. The physical manifestations, diarrhea status were monitored during the drug delivery. Histopathology of colon, intestinal microbiota, inflammatory cytokines, tight junction protein and short chain fat acids (SCFAs) were determined.
Mice received cefuroxime and levofoxacin for 5 days developed medium to severe diarrhea. XLP treatment, however, mitigated the diarrhea status. Further evaluation revealed that XLP promoted the recovery of mucosa, maintained the integrity of tight junction, attenuated the inflammatory disorders, restored intestinal microbiota and increased SCFAs level in feces.
XLP ameliorates AAD by restoring intestinal microbiota and attenuating mucosal damage.
香连丸（XLP）是一种传统的中药制剂，用于治疗胃肠道疾病，具有抗炎、抗菌和镇痛作用，可能是治疗抗生素相关性腹泻（AAD）的有前途的候选药物。
本研究旨在揭示 XLP 改善 AAD 的潜在机制。
通过连续 5 天给予头孢呋辛和左氧氟沙星（300mg/kg.bw+200mg/kg.bw）混合物灌胃来诱导 AAD。然后，用 XLP 以 500、1000 和 2000mg/kg.bw 的剂量分别治疗 AAD 小鼠 5 天。在药物给药期间监测身体表现和腹泻状况。测定结肠组织病理学、肠道微生物群、炎症细胞因子、紧密连接蛋白和短链脂肪酸（SCFAs）。
连续 5 天接受头孢呋辛和左氧氟沙星治疗的小鼠出现中度至重度腹泻。然而，XLP 治疗减轻了腹泻状况。进一步评估显示，XLP 促进了粘膜的恢复，维持了紧密连接的完整性，减轻了炎症紊乱，恢复了肠道微生物群，并增加了粪便中的 SCFAs 水平。
XLP 通过恢复肠道微生物群和减轻粘膜损伤来改善 AAD。
